Novavax shares soared after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Madison Muller reports on Bloomberg Television. (Source: Bloomberg)
The major stock market indexes (^DJI, ^IXIC, ^GSPC) are on the road to closing out the first full trading week of May on a high note, alongside several of its European counterparts: the FTSE 100 (^FTSE), the DAX Performance Index (^GDAXI), and the CAC 40 (^FCHI). President Biden is reportedly set to announce updates on Trump-era trade tariffs on China. Novavax (NVAX) shares are skyrocketing over 110% on news of the biotech company's plans to licensing deal with Sanofi (SNY, SAN.PA) to...
The past five days have been a rollercoaster for Novavax investors, as the share price of the company skyrocketed by over 200% following the announcement of a major deal with French pharmaceutical giant Sanofi.
It's a major turnaround for a drug company that warned last year about its
Novavax (NVAX) shares are skyrocketing after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu shot. Yahoo Finance's Anjalee Khemlani joins The Morning Brief to report more on the story. The Novavax-Sanofi deal also includes co-commercialization of the COVID-19 vaccine currently on the market. Novavax will be entitled to an additional $200 million for any new vaccines involving its adjuvant. Sanofi will receive a minority stake of less than 5% in...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot.
Novavax agreed to license its vaccine technology to French drugmaker Sanofi to co-commercialize its COVID-19 vaccine, and also develop other vaccines.
Novavax said the deal with Sanofi allows it to remove its "going concern" warning, which it first issued last year due to doubts about staying afloat.
The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial doubt" about its ability to survive.
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients...